Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)
Completed · Phase 1 · NCT07158411
Conditions: Healthy Participants
At a glance
- Research payments reported, 2025
- $702,014
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 22
About the trial
- Sponsor
- Deciphera Pharmaceuticals, LLC
- Tested
- Vimseltinib (drug), Metformin (drug)
- Dates
- Started 2025-11-20; completion 2026-01-30
- Results posted
- Not yet
The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants. This study will also assess the safety and tolerability when vimseltinib is co-administered with the clinical OCT2 substrate (metformin) in healthy male participants. This study will last approximately 25 days.
From ClinicalTrials.gov, last updated 2026-02-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Deciphera Pharmaceuticals Inc. reported $702,014 in research payments for this study in 2025 (7 payments).
Products named: Metformin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dr Vince Clinical Research $700,397
- Dr Vince Clinical Resarch LLC $1,617
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.